In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest ...

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...

Aurion is developing AURN001, a clinical-stage allogeneic cell therapy asset, for corneal edema secondary to corneal ...

New phase 3 data provide reassurance on safety, tolerability, and overall benefit-risk of mirvetuximab soravtansine (Elahere) ...

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired a majority interest in Aurion Biotech, Inc., a clinical-stage company ...

Alcon said that its majority stake means that Aurion will have "broader R&D, regulatory, medical ophthalmic, and commercial ...

Ocular AEs linked to mirvetuximab soravtansine do not appear to reduce HRQOL in patients with FRα+ platinum-resistant ovarian cancer.

Mirvetuximab soravtansine improved overall survival, progression-free survival, second progression-free survival, and other outcomes.

Clinical trials of liquid cornea, which can end the dependence upon human cornea donors for the treatment of corneal ...

Manuscripts can be submitted to this Research Topic via the main journal or any other participating journal.

Corneal disease is the primary cause of visual loss in allergic eye disease. It occurs almost exclusively in vernal keratoconjunctivitis and atopic keratoconjunctivitis. It is characterized by ...